Extract
For obstructive sleep apnea (OSA), few mechanical treatment options are available and no pharmacotherapy is approved [1–3]. However, safe and efficacious pharmacotherapy would have substantial appeal for many people with OSA.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Gaisl reports personal fees from Bayer, during the conduct of the study.
Conflict of interest: Dr. Turnbull reports personal fees from Bayer Germany, during the conduct of the study.
Conflict of interest: Dr. Weimann reports being a full time employee of Bayer Pharma AG.
Conflict of interest: S. Unger reports other from Bayer Pharma AG, outside the submitted work.
Conflict of interest: Dr. Finger reports and employee of the sponsor.
Conflict of interest: Dr. Xing reports and employee of the sponsor.
Conflict of interest: PAC has an appointment to an endowed academic Chair at the University of Sydney that was created from ResMed funding. He receives no personal fees and this relationship is managed by an Oversight Committee of the University. He has received research support from ResMed, SomnoMed, Zephyr Sleep Technologies, and Bayer. He is a consultant/adviser to Bayer, Zephyr Sleep Technologies, Signifier Medical Technologies, SomnoMed, and ResMed. He has a pecuniary interest in SomnoMed related to a previous role in R&D (2004).
Conflict of interest: Dr. West reports personal fees from Bayer, during the conduct of the study.
Conflict of interest: Dr. Chiang reports grants from Bayer, grants from Cooperative Research Centre Project Grant.
Conflict of interest: Dr. Eckert reports grants from National Health and Medical Research Council of Australia, grants and personal fees from Bayer, during the conduct of the study; grants and personal fees from Apnimed, outside the submitted work.
Conflict of interest: Dr. STRADLING reports grants from Bayer who sponsored this trial through payments to Oxford University Hospitals, personal fees from Bayer, during the conduct of the study; personal fees from Resmed UK, outside the submitted work; .
Conflict of interest: Dr. Kohler reports grants and personal fees from Bayer, during the conduct of the study; personal fees from Novartis, grants and personal fees from GSK, grants and personal fees from Roche, personal fees from Boehringer Ingelheim, personal fees from Mundipharma, personal fees from OM Pharma, personal fees from Astra Zeneca, outside the submitted work; and Malcolm Kohler is a founder and board member of Deep Breath Intelligence Ltd, a company that provides services in the field of breath analysis.
- Received July 2, 2021.
- Accepted August 23, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org